Nuevolution Appoints Henrik Simonsen
News Sep 17, 2015
Nuevolution A/S has announced that Henrik Simonsen has joined the company in the position as Chief Financial Officer. In his role, Mr. Simonsen will lead Nuevolution’s financial strategy including corporate finance and investor relations.
As member of Nuevolution’s Executive Management, he will play a key part in the strategy planning going forward. His most recent position was at SEB, where he was Sector Responsible for the Life Science arm of the Corporate Finance practice.
With Henrik Simonsen, Nuevolution appoints a seasoned professional, who has over 20 years of experience as an equity analysts covering Nordic, European and US life science companies as well as a number of years of corporate finance experience including several biotech IPO’s in Scandinavia.
“The appointment of Henrik Simonsen, to take charge of Nuevolution’s financial strategy and investor relations, represents an important step for Nuevolution in realization of our ambitious strategy of establishing a broad portfolio of clinical and pre-clinical programs within oncology, immunology and immuno-oncology.” said Alex Gouliaev, CEO of Nuevolution A/S and continued “Our programs addresses diseases with significant unmet need, and should therefore be developed as rapidly as possible. With Henrik’s strong corporate finance experience and investor network, we are confident that he will play a key role in helping secure future financing needed in realization of these important goals.”
“I am thrilled to be joining Nuevolution, which has developed the state-of-the art drug discovery platform, Chemetics, collaborates with leading drug companies and is building a promising pipeline in oncology, immuno-oncology and inflammation”, says Henrik Simonsen.
Most recently, Henrik served as Director and Sector Responsible for Life Science within Corporate Finance at SEB, where he was leading a number of Initial Public Offerings, venture capital raising initiatives as well as acting as an advisor to the executive management of several pharmaceutical and biotech companies.
Prior to SEB Corporate Finance, Henrik was Senior Equity Analyst at SEB and at Nordea Securities. Henrik obtained his Master of Science in Economics degree from the University of Copenhagen.
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
Tiny Particles Carry Tumor Shrinking Drugs into the BrainNews
MIT researchers have now devised a new drug-delivering nanoparticle that could offer a better way to treat glioblastoma. The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumor cells.READ MORE
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous SclerosisNews
Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018